Aligos Therapeutics Inc logo

ALGS - Aligos Therapeutics Inc Share Price

$15.72 -0.1  -0.3%

Last Trade - 22/10/21

Mid Cap
Market Cap £487.1m
Enterprise Value £348.8m
Revenue £1.79m
Position in Universe 3403rd / 7261
Unlock ALGS Revenue
Relative Strength (%)
1m -1.78%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -58.1%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000 2.38
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 30 June 2021, AligosTherapeutics Inc revenues increased from $0K to $2.5M. Netloss increased 41% to $57.5M. Revenues reflect an increasein demand for the Company's products and services due tofavorable market conditions. Higher net loss reflectsResearch and development increase of 56% to $39M (expense),Stock-based Compensation in R&D increase from $350K to$3.5M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


ALGS Revenue Unlock ALGS Revenue

Net Income

ALGS Net Income Unlock ALGS Revenue

Normalised EPS

ALGS Normalised EPS Unlock ALGS Revenue

PE Ratio Range

ALGS PE Ratio Range Unlock ALGS Revenue

Dividend Yield Range

ALGS Dividend Yield Range Unlock ALGS Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
ALGS EPS Forecasts Unlock ALGS Revenue
Profile Summary

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapeutics to address unmet medical needs in viral and liver diseases. It uses its oligonucleotide and small molecule platforms to develop pharmacologically optimized drug candidates for use in combination regimens. It is initially focused on developing functional cure for Chronic Hepatitis B (CHB); cirrhosis, end-stage liver disease (ESLD) and hepatocellular carcinoma (HCC). It developing a portfolio of differentiated drug candidates for CHB, including an S-antigen Transport-inhibiting Oligonucleotide Polymers (STOPS) molecule, a small molecule Capsid Assembly Modulator (CAM), and oligonucleotides, such as ASO and Small interfering RNA (siRNA), each of which is designed against targets in the Hepatitis B Virus (HBV) life cycle. The Company's pipeline includes ALG-010133, ALG-000184, ALG-020572, ALG-125097 and ALG-055009.

Last Annual December 31st, 2020
Last Interim June 30th, 2021
Incorporated February 5, 2018
No. of Shareholders: 99
No. of Employees: 86
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 42,608,792
Free Float (0.0%)
Eligible for
ALGS Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ALGS
Upcoming Events for ALGS
Frequently Asked Questions for Aligos Therapeutics Inc
What is the Aligos Therapeutics Inc share price?

As of 22/10/21, shares in Aligos Therapeutics Inc are trading at $15.72, giving the company a market capitalisation of £487.1m. This share price information is delayed by 15 minutes.

How has the Aligos Therapeutics Inc share price performed this year?

Shares in Aligos Therapeutics Inc are currently trading at $15.72 and the price has moved by 4.31% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Aligos Therapeutics Inc price has moved by -20.55% over the past year.

What are the analyst and broker recommendations for Aligos Therapeutics Inc?

There are no analysts currently covering Aligos Therapeutics Inc.

When will Aligos Therapeutics Inc next release its financial results?

Aligos Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-06-30
What is the Aligos Therapeutics Inc dividend yield?

Aligos Therapeutics Inc does not currently pay a dividend.

Does Aligos Therapeutics Inc pay a dividend?

Aligos Therapeutics Inc does not currently pay a dividend.

When does Aligos Therapeutics Inc next pay dividends?

Aligos Therapeutics Inc does not currently pay a dividend.

How do I buy Aligos Therapeutics Inc shares?

To buy shares in Aligos Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Aligos Therapeutics Inc?

Shares in Aligos Therapeutics Inc are currently trading at $15.72, giving the company a market capitalisation of £487.1m.

Where are Aligos Therapeutics Inc shares listed? Where are Aligos Therapeutics Inc shares listed?

Here are the trading details for Aligos Therapeutics Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: ALGS
What kind of share is Aligos Therapeutics Inc?

Based on an overall assessment of its quality, value and momentum, Aligos Therapeutics Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Aligos Therapeutics Inc share price forecast 2021?

Shares in Aligos Therapeutics Inc are currently priced at $15.72. At that level they are trading at 0.121% discount to the analyst consensus target price of 0.00.

Analysts covering Aligos Therapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -3.08 for the next financial year.

How can I tell whether the Aligos Therapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aligos Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been -40.87%. At the current price of $15.72, shares in Aligos Therapeutics Inc are trading at -28.01% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Aligos Therapeutics Inc PE Ratio?

We were not able to find PE ratio data for Aligos Therapeutics Inc.

Who are the key directors of Aligos Therapeutics Inc?

Aligos Therapeutics Inc's management team is headed by:

Lawrence Blatt - CEO
Leonid Beigelman - PRE
Julian Symons - EVP
Lucinda Quan - EVP
James Scopa - IND
Peter Moldt - IND
K. Peter Hirth - IND
Jack Nielsen - NEC
Carole Nuechterlein - IND
Lesley Calhoun - CFO
Who are the major shareholders of Aligos Therapeutics Inc?

Here are the top five shareholders of Aligos Therapeutics Inc based on the size of their shareholding:

Wellington Management Company, LLP Investment Advisor/Hedge Fund
Percentage owned: 10.57% (4.18m shares)
Vivo Capital, LLC Venture Capital
Percentage owned: 8.98% (3.55m shares)
Roche Holding AG Holding Company
Percentage owned: 7.83% (3.09m shares)
Logos Global Management LLC Investment Advisor
Percentage owned: 7.27% (2.87m shares)
Novo Holdings A/S Venture Capital
Percentage owned: 6.62% (2.61m shares)
Similar to ALGS
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.